Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker NBIS
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Marc Boroditsky Chief Revenue Officer | NBIS Nebius Group N.V. | Sale | 7,000 | $147.97 | $1.0M Sale | Form 4 ↗ |
| Oct 29, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 333 | $173.07 | $57.6K Sale | Form 4 ↗ |
| Oct 29, 2026 | Arne Grimme Director | NBIS Nebius Group N.V. | Buy | 148 | $169.42 | $25.1K Buy | Form 4 ↗ |
| Oct 28, 2026 | Arne Grimme Director | NBIS Nebius Group N.V. | Buy | 148 | $169.84 | $25.1K Buy | Form 4 ↗ |
| Oct 27, 2026 | Arne Grimme Director | NBIS Nebius Group N.V. | Buy | 205 | $159.04 | $32.6K Buy | Form 4 ↗ |
| Oct 26, 2026 | Arne Grimme Director | NBIS Nebius Group N.V. | Buy | 208 | $153.96 | $32.0K Buy | Form 4 ↗ |
| Oct 23, 2026 | Arne Grimme Director | NBIS Nebius Group N.V. | Buy | 205 | $158.98 | $32.6K Buy | Form 4 ↗ |
| Oct 22, 2026 | Arne Grimme Director | NBIS Nebius Group N.V. | Buy | 357 | $161.97 | $57.8K Buy | Form 4 ↗ |
| Oct 21, 2026 | Arne Grimme Director | NBIS Nebius Group N.V. | Buy | 148 | $167.94 | $24.9K Buy | Form 4 ↗ |
| Oct 20, 2026 | Arne Grimme Director | NBIS Nebius Group N.V. | Buy | 151 | $164.62 | $24.9K Buy | Form 4 ↗ |
| Oct 19, 2026 | Arne Grimme Director | NBIS Nebius Group N.V. | Buy | 148 | $169.99 | $25.2K Buy | Form 4 ↗ |
| Oct 16, 2026 | Arne Grimme Director | NBIS Nebius Group N.V. | Buy | 148 | $169.99 | $25.2K Buy | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 100 | $188.77 | $18.9K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 960 | $188.20 | $180.7K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 400 | $186.67 | $74.7K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 200 | $184.35 | $36.9K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 200 | $182.21 | $36.4K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 400 | $181.27 | $72.5K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 600 | $180.26 | $108.2K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 400 | $179.03 | $71.6K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 400 | $177.90 | $71.2K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 700 | $176.72 | $123.7K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 500 | $175.72 | $87.9K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 400 | $174.70 | $69.9K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 200 | $172.59 | $34.5K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 400 | $171.38 | $68.6K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 100 | $170.00 | $17.0K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 100 | $168.57 | $16.9K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 500 | $167.80 | $83.9K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 500 | $166.78 | $83.4K Sale | Form 4 ↗ |
| Oct 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 200 | $164.80 | $33.0K Sale | Form 4 ↗ |
| Oct 15, 2026 | Arne Grimme Director | NBIS Nebius Group N.V. | Buy | 148 | $169.99 | $25.2K Buy | Form 4 ↗ |
| Sep 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 100 | $216.52 | $21.7K Sale | Form 4 ↗ |
| Sep 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 200 | $215.59 | $43.1K Sale | Form 4 ↗ |
| Sep 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 900 | $214.81 | $193.3K Sale | Form 4 ↗ |
| Sep 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 300 | $213.40 | $64.0K Sale | Form 4 ↗ |
| Sep 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 200 | $211.88 | $42.4K Sale | Form 4 ↗ |
| Sep 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 400 | $210.53 | $84.2K Sale | Form 4 ↗ |
| Sep 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 1,100 | $209.74 | $230.7K Sale | Form 4 ↗ |
| Sep 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 1,900 | $208.84 | $396.8K Sale | Form 4 ↗ |
| Sep 15, 2026 | John Wilson Boynton IV Director | NBIS Nebius Group N.V. | Sale | 1,264 | $207.67 | $262.5K Sale | Form 4 ↗ |
| Sep 14, 2026 | Marc Boroditsky Chief Revenue Officer | NBIS Nebius Group N.V. | Sale | 2,000 | $208.63 | $417.3K Sale | Form 4 ↗ |
| Sep 14, 2026 | Marc Boroditsky Chief Revenue Officer | NBIS Nebius Group N.V. | Sale | 5,000 | $209.26 | $1.0M Sale | Form 4 ↗ |
| Sep 1, 2026 | Maria del Dado Alonso Sanchez CFO | NBIS Nebius Group N.V. | Sale | 470 | $196.00 | $92.1K Sale | Form 4 ↗ |
| Aug 14, 2026 | Charles E. Ryan Director | NBIS Nebius Group N.V. | Sale | 2,667 | $269.64 | $719.1K Sale | Form 4 ↗ |
| Aug 14, 2026 | Charles E. Ryan Director | NBIS Nebius Group N.V. | Sale | 5,000 | $268.61 | $1.3M Sale | Form 4 ↗ |
| Aug 14, 2026 | Charles E. Ryan Director | NBIS Nebius Group N.V. | Sale | 9,622 | $266.67 | $2.6M Sale | Form 4 ↗ |
| Aug 14, 2026 | Charles E. Ryan Director | NBIS Nebius Group N.V. | Sale | 10,113 | $265.45 | $2.7M Sale | Form 4 ↗ |
| Aug 14, 2026 | Charles E. Ryan Director | NBIS Nebius Group N.V. | Sale | 9,283 | $264.78 | $2.5M Sale | Form 4 ↗ |
| Aug 14, 2026 | Charles E. Ryan Director | NBIS Nebius Group N.V. | Sale | 13,315 | $263.32 | $3.5M Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:26 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances